Xoma Royalty (XOMA) Return on Equity ROE from the first quarter 2026 to first quarter 2025 and annually, average high and low, overall ranking from Mar 31 2026 to Mar 31 2025 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Xoma Royalty Corporation  (NASDAQ: XOMA)

Xoma Royalty's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Xoma Royalty in the first quarter 2026?
Xoma Royalty Corporation achieved a return on average equity (ROE) of 23.64 % in its first quarter 2026, this is above XOMA's average return on equity of -282.93%.
Xoma Royalty Corporation shareholder's equity over the 12 months ending in its first quarter 2026 are valued at $84 million

ROE decreased relative to the period ending , due to the decline in net income.

Within the Major Pharmaceutical Preparations industry 33 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the fourth quarter 2025 from 491 to 560.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter
Y / Y Equity Change 43.75 % 35.6 % 35.73 % -9.43 % -
Y / Y Net Income Change 200.85 % - - -45.99 % -
Net Income (TTM) in Millions 20 19 13 -15 -10
Return On Equity (TTM) 23.64 % 23.97 % 17.98 % -22.29 % -14.73 %
XOMA's Total Ranking # 560 # 491 # 798 # 2485 # 2516
Equity (TTM) in Millions 93 84 88 72 65
Seq. Equity Change 10.64 % -4.55 % 21.4 % 12.11 % 4.37 %
Seq. Net Income Change -35.88 % -63.17 % 62.64 % 683.26 % -

Back to XOMA Management Effectiveness >> XOMA's 5 Years Annual ROE >> Compare XOMA ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 34
Sector # 73
Overall # 560

Return On Equity Statistics
High Average Low
184.68 %
-282.93 %
-6055.22 %
(Jun 30 2018)   (Mar 31 2013)





XOMA Annual Return On Equity (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Equity in Millions 84 82 89 124 142
Y / Y Equity Change 2.47 % -7.66 % -28.46 % -12.59 % 64.16 %
Net Income in Millions 19 -19 -46 -23 8
Y / Y Net Income Change - - - - -11.44 %
Return On Equity 22.06 % -23.55 % -52.19 % -18.2 % 5.49 %

Back to XOMA Management Effectiveness >> XOMA's 5 Years Annual ROE >> Compare XOMA ROE to its Competitors




Annual Roe Comment
In 2025 ROE improved to 22.06 % compared to the previous year, due to net income growth.


More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
XOMA's' Return on Equity at Yahoo Finance
XOMA's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for XOMA's Competitors
Subscribers only: Roe for Xoma Royalty's Suppliers
Subscribers only: Return On Equity for XOMA's Customers




Companies with similar Return On Equity at Mar 31 2026, within Healthcare Sector ROE
Aurinia Pharmaceuticals Inc   64.48 %
Lifemd Inc   63.70 %
Zoetis Inc   61.63 %
Vaxart Inc   61.43 %
Dariohealth Corp   60.52 %
Nrc Health  57.25 %
Oramed Pharmaceuticals Inc  55.40 %
Innoviva Inc   47.59 %
Concentra Group Holdings Parent Inc   46.95 %
Liquidia Corporation  46.82 %
Agilent Technologies inc   44.45 %
Tenet Healthcare Corp  44.20 %
Theravance Biopharma inc   43.85 %
Gilead Sciences Inc   42.33 %
Transmedics Group Inc   41.92 %
Abeona Therapeutics Inc   41.40 %
Apellis Pharmaceuticals Inc   39.71 %
Adma Biologics Inc   38.97 %
Bristol myers Squibb Company  38.94 %
Acadia Pharmaceuticals Inc   35.65 %
Spero Therapeutics Inc   35.58 %
Illumina Inc   33.99 %
Dexcom Inc   33.83 %
Rafael Holdings Inc  31.93 %
Solventum Corporation  30.71 %
Phibro Animal Health Corporation  30.60 %
Pro dex Inc   30.01 %
Incyte Corporation  29.20 %
Protalix Biotherapeutics inc   28.10 %
Collegium Pharmaceutical Inc   26.74 %

Date modified: 2026-09-18T13:11:06+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.